ANSONIA, CT, Arrien Pharmaceuticals LLC (Arrien), a new start-up company located in the Connecticut & Salt Lake City areas, announced a successful completion of Series A financing from contributions by the founders of the company and currently engaged in the discovery and development of breakthrough novel small molecules targeting cell signaling pathways.

Arrien Pharmaceuticals is a small molecule targeted therapeutics drug discovery and development company working towards targeting cell signaling pathways - A target class in treating neurodegenerative, Cancer, Inflammatory and Metabolic diseases. The Arrien is applying its proprietary platform to successfully discover a portfolio of uniquely identified pre-clinical stage programs in Parkinson's, Alzheimer's Diseases (PD, AD), Cancer, Rheumatoid Arthritis (RA), Type 2 Diabetes and Obesity diseases.